Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 13/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 5/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.51 |
| ▸ | GRM5 | P41594 | 3/20 | 0.45 |
| ▸ | MAOB | P27338 | 2/20 | 0.45 |
| ▸ | MAOA | P21397 | 1/20 | 0.45 |
| ▸ | SYK | P43405 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4493029 | 0.86 | CNR2 (0.54) | CNR2CYP3A4CYP2C9CYP2C19CYP1A2 | |
| SCHEMBL4479173 | 0.81 | CNR2 (0.72) | CNR2CYP3A4CYP2C9CYP2C19CYP1A2 | |
| SCHEMBL4479541 | 0.81 | HDAC3 (0.51) | CNR2CYP3A4CYP2C9CYP2C19CYP1A2 | |
| SCHEMBL4471408 | 0.75 | SIRT5 (0.56) | CNR2CYP2C9CYP2C19CYP1A2SYK | |
| SCHEMBL13672506 | 0.75 | CAMK2D (0.49) | CNR2CYP3A4CYP2C9CYP2C19CYP1A2 | |
| SCHEMBL13672507 | 0.75 | CNR2 (0.73) | CNR2CYP3A4CYP2C9CYP2C19CYP1A2 | |
| Hydrochloric Acid SCHEMBL4471954 | 0.74 | CAMK2D (0.48) | CNR2CYP3A4CYP2C9CYP2C19CYP1A2 | |
| SCHEMBL3378679 | 0.74 | CNR2 (0.71) | CNR2CYP3A4CYP2C9CYP2C19CYP1A2 | |
| SCHEMBL4894761 | 0.74 | SYK (0.51) | CNR2GRM5MAOBMAOASYK | |
| SCHEMBL3379907 | 0.73 | CNR2 (0.54) | CNR2CYP3A4CYP2C9CYP2C19CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090264452-A1 | 2-(Phenylamino)-Pyrimidin-5-Amides As Cannabinoid 2 Receptors Modulators for the Treatment of Immune or Inflammatory Disorders | GLAXO GROUP LIMITED (GB) | 2009-10-22 | — | — | US | disclosed |
| EP-1711475-A1 | 2-(PHENYLAMINO)-PYRIMIDIN-5-AMIDES AS CANNABINOID 2 RECEPTORS MODULATORS FOR THE TREATMENT OF IMMUNE OR INFLAMMATORY DISORDERS. | GLAXO GROUP LIMITED (GB) | 2006-10-18 | — | — | EP | disclosed |
| WO-2005075440-A1 | 2- (PHENYLAMINO) -PYRIMIDIN-5-AMIDES AS CANNABINOID 2 RECEPTORS MODULATORS FOR THE TREATMENT OF IMMUNE OR INFLAMMATORY DISORDERS | GLAXO GROUP LIMITED (GB) | 2005-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264452-A1 | 2-(Phenylamino)-Pyrimidin-5-Amides As Cannabinoid 2 Receptors Modulators for the Treatment of Immune or Inflammatory Disorders | CNR2, CNR1, P2RY2 | CNR2 1/4885CYP3A4 2324/4885CYP2C9 1051/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.